Methods and compositions for treating hypoglycemic disorders
AssigneesThe Trustees of the University of Pennsylvania, The Children's Hospital of Philadelphia
InventorsDoris Stoffers, Diva D. De Leon, Charles Stanley
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analogue thereof.
Claims19
A method of treating a subject with a congenital hyperinsulinism, or neonatal hyperinsulinism, comprising the step of administering to said subject an antagonist of the Glucagon Like Peptide-1 (GLP-1) receptor, thereby decreasing basal intracellular cAMP and treating a subject with a congenital hyperinsulinism.
A method of inhibiting or suppressing congenital hyperinsulinism or neonatal hyperinsulinism, comprising the step of administering to said subject an antagonist of the Glucagon Like Peptide-1 (GLP-1) receptor, thereby decreasing basal intracellular cAMP and inhibiting or suppressing congenital hyperinsulinism.
A method of reducing symptoms associated with congenital hyperinsulinism or neonatal hyperinsulinism, comprising the step of administering to said subject an antagonist of the Glucagon Like Peptide-1 (GLP-1) receptor, thereby decreasing basal intracellular cAMP and reducing symptoms associated with congenital hyperinsulinism
A method of reducing an incidence of hypoglycemia in a subject with neonatal HI, comprising the step of administering to said subject an antagonist of the Glucagon Like Peptide-1 (GLP-1) receptor, thereby decreasing basal intracellular cAMP and reducing an incidence of hypoglycemia in a subject with neonatal HI.
Dependencies are inferred from the claim text.